DXCM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dexcom Inc (DXCM) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial performance in its latest quarter and analysts have generally positive ratings with increased price targets, the technical indicators and trading signals do not support an immediate entry point. The stock is currently in a bearish trend with no clear positive momentum, and there are no significant catalysts or recent news to drive the stock upward in the short term. For a long-term investor, waiting for a more favorable entry point or stronger bullish signals would be prudent.
The stock is in a bearish trend with the MACD histogram below 0 and negatively contracting. RSI is neutral at 38.15, and moving averages indicate bearish momentum (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 64.481) but shows no clear reversal signals.
Strong financial performance in Q4 2025 with revenue up 13.12% YoY, net income up 76.20% YoY, and EPS up 81.08% YoY. Analysts have raised price targets, and the company remains a leader in glucose monitoring technology.
Bearish technical indicators and lack of recent news or significant trading trends. The stock has a 50% chance of declining by -5.64% in the next month based on similar candlestick patterns. No recent congress trading data or influential figure activity.
In Q4 2025, Dexcom reported revenue of $1.2596 billion (+13.12% YoY), net income of $267.3 million (+76.20% YoY), EPS of 0.67 (+81.08% YoY), and a gross margin of 70.3% (+10.36% YoY).
Analysts are generally positive on DXCM, with multiple firms raising their price targets recently. The highest target is $95 (Canaccord), and the lowest is $72 (Barclays). Most analysts maintain Buy or Outperform ratings, citing strong fundamentals and growth potential in the glucose monitoring market.
